These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15319086)

  • 1. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
    Jones CA; Cunningham AL
    Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
    Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
    J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
    Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
    N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of prophylactic vaccines for genital and neonatal herpes.
    Jones CA; Cunningham AL
    Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
    Pepose JS; Keadle TL; Morrison LA
    Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on short-course episodic and prevention therapies for herpes genitalis.
    Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
    Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines.
    Schwartz EJ; Blower S
    J Infect Dis; 2005 May; 191(10):1734-46. PubMed ID: 15838802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
    Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
    Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatrics and herpes simplex virus vaccines.
    Rupp R; Rosenthal SL; Stanberry LR
    Semin Pediatr Infect Dis; 2005 Jan; 16(1):31-7. PubMed ID: 15685147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.